DoW Pancreatic Cancer Research Program, Idea Development Award | HT942526PCARPIDA

Frequently Asked Questions (FAQ) - FY26 DoD Pancreatic Cancer Research Program (PCARP) Idea Development Award

1) What is the FY26 DoD PCARP Idea Development Award?

The FY26 Department of Defense (DoD) Pancreatic Cancer Research Program (PCARP) Idea Development Award is a discretionary grant opportunity administered by the U.S. Army Medical Research Acquisition Activity (USAMRAA). It is designed to push pancreatic cancer research in bold, inventive directions by supporting innovative, high-risk/high-reward projects.

2) What is the main goal of this award?

The core goal is to fund research that has a realistic chance of producing critical discoveries or major advances that could speed progress toward better outcomes for people diagnosed with pancreatic cancer. The program is intended to generate impactful data and open new lines of investigation rather than fund incremental extensions of well-established work.

3) What type of research is this opportunity trying to encourage?

This opportunity emphasizes innovative, high-risk/high-reward ideas. Projects should be bold and inventive, with the potential to create major advances or critical discoveries in pancreatic cancer research, rather than small, incremental improvements to existing approaches.

4) Do proposals have to fit specific program priorities?

Yes. Every application must align with at least one of the FY26 PCARP Focus Areas. Proposals need to clearly match the program's current priority topics and cannot rely on being broadly relevant to cancer in general.

5) Are applicants required to include preliminary data?

Yes. Applicants must include preliminary data that is directly relevant to the proposed project. This requirement signals that the proposed concept has supporting evidence, even if the overall approach is exploratory or unconventional.

6) Does the award support clinical research?

Clinical research studies may be supported under this mechanism, but clinical trials are not permitted. Applicants should design any human-focused work accordingly (for example, observational or correlative studies, biomarker work, or analyses using existing samples or datasets, if consistent with the solicitation rules).

7) Are clinical trials allowed under this award?

No. The mechanism does not permit clinical trials. Applicants should ensure that any clinical components are structured as non-trial clinical research, consistent with the rules described in the full solicitation.

8) What is the Early-Career Investigator partnering option?

The award includes an Early-Career Investigator partnering track intended to help build the next generation of pancreatic cancer researchers. In this option, a more experienced researcher serves as the Initiating Principal Investigator (PI) and mentor, while an Early-Career Investigator serves as the Partnering PI and leads a distinct portion of the overall project.

9) How do the Initiating PI and Partnering PI roles differ?

The Initiating PI is the more experienced researcher and serves as the mentor. The Early-Career Investigator is the Partnering PI and is responsible for leading a defined, distinct part of the overall research effort.

10) Does the partnering option affect the funding level?

Yes. The Early-Career Investigator partnering track allows for a higher level of funding compared with a standard single-PI submission, reflecting the added value of mentorship and workforce development.

11) How does the submission process work for the partnering track?

The submission process is staged. Only the Initiating PI submits the pre-application. If invited to the full application stage, both the Initiating PI and the Partnering PI must submit their materials.

12) What does the Partnering PI submit at the full application stage?

The Partnering PI submits an abbreviated application that focuses specifically on their defined part of the research project.

13) Are the initiating and partnering submissions reviewed as a single package?

Yes. The linked applications are treated as a package. If either the initiating or partnering application is rejected or withdrawn for administrative reasons, the entire associated project may be withdrawn as well.

14) Who can apply for this opportunity?

Eligibility is listed as unrestricted, suggesting a wide range of applicant organizations may apply, as long as they meet the solicitation's requirements.

15) What is the Funding Opportunity Number for this grant?

The Funding Opportunity Number is HT942526PCARPIDA.

16) What type of funding mechanism is this?

This opportunity is categorized as a grant and falls under the Science and Technology / Research and Development area.

17) What CFDA number is associated with this opportunity?

The CFDA number listed is 12.420.

18) When was this opportunity created and when does it close?

The opportunity was created on 2026-05-04. The original closing date is 2026-10-07.

19) How many awards does the program expect to make?

The program anticipates making about 12 awards.

20) What is the maximum award amount (award ceiling)?

The award ceiling is not specified in the provided information. Applicants would need to consult the full announcement for exact budget limits, period of performance details, and any cost rules.

21) Where can applicants find budget limits, performance period details, and cost rules?

Because the award ceiling and other detailed budget and performance rules are not included in the provided text, applicants should refer to the full funding announcement for the official requirements and limitations.